Skip to search formSkip to main contentSkip to account menu

ZSTK474

Known as: PI3K Inhibitor ZSTK474, Phosphatidylinositol 3-kinase Inhibitor ZSTK474 
An orally available, s-triazine derivative, ATP-competitive phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
A structure-activity relationship (SAR) study of the pan class I PI 3-kinase inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl… 
Review
2010
Review
2010
AbstractJFCR39 is an informatic anticancer drug discovery system that utilizes a panel of 39 human cancer cells coupled with a… 
Highly Cited
2009
Highly Cited
2009
Phosphatidylinositol 3-kinase (PI3K) has been implicated in a variety of diseases including cancer. A number of PI3K inhibitors… 
Review
2009
Review
2009
Phosphatidylinositol 3-kinases (PI3Ks) are a class of lipid kinases that phosphorylate phosphatidylinositol 4,5-bisphosphate… 
Highly Cited
2007
Highly Cited
2007
Class I phosphatidylinositol 3 kinases (PI3K) phosphorylate phosphatidylinositol 4,5‐bisphosphate to generate… 
Highly Cited
2006
Highly Cited
2006
BACKGROUND We previously synthesized a novel s-triazine derivative, ZSTK474 [2-(2-difluoromethylbenzimidazol-1-yl)-4,6…